Overview

Pharmacodynamic Study of Goserelin 3.6mg Injection Administered Subcutaneously in Premenopausal Patients With Advanced Breast Cancer

Status:
Unknown status

Trial end date:
2020-11-01

Target enrollment:

Participant gender:

Summary

A two arm, multi centric, randomized, open label, parallel, multiple dose pharmacodynamic study in premenopausal patients with advanced breast cancer.

Phase:

Phase 3

Details

Lead Sponsor:

Eurofarma Laboratorios S.A.

Treatments:

Goserelin